Intestinal stem cells may have important roles in the maintenance of epithelial integrity during tissue repair. Alemtuzumab is a humanized anti-CD52 lymphocytic antibody that is increasingly being used to induce immunosuppression; intestinal barrier function is impaired during treatment with alemtuzumab. We investigated the response of intestinal stem cells to epithelial damage resulting from alemtuzumab treatment. Intestinal epithelial cell loss and abnormal Paneth cell morphology were found following a single dose of alemtuzumab. The animals receiving alemtuzumab exhibited increased apoptosis in the villi 3 days after alemtuzumab treatment and in the crypt on day 9, but apoptosis was scarce on day 35. We assessed expression of Musashi-1-and Lgr5-positive stem cells following alemtuzumab treatment. Increased numbers of cells staining positive for both Musashi-1 and Lgr5 were found in the stem cell zone after alemtuzumab treatment for 3 and 9 days. These data indicated that the epithelial cells were injured following alemtuzumab treatment, with the associated expansion of intestinal stem cells. After alemtuzumab treatment for 35 days, the numbers of intestinal epithelial cells and intestinal stem cells returned to normal. This study suggests that alemtuzumab treatment induced the increase in stem cells, resulting in the availability of more enterocytes for repair.
INTRODUCTION
The intestinal epithelium is composed of four lineages of intestinal epithelial cells that arise from intestinal stem cells (ISCs) . 1 ISCs at the crypt bottom play a critical role in maintaining homeostasis of the intestinal epithelium. 2, 3 Damage to the intestinal epithelium resulting in destruction of the epithelial barrier is observed in a wide variety of diseases, such as intestinal infections, radiation injuries or idiopathic inflammatory bowel diseases, and following exposure to chemical agents. 4 Once the epithelial layer is damaged, it responds by restoring the continuity and integrated structure by activating the stepwise regeneration program. 5 Restoration of normal epithelial architecture after intestinal injury may ultimately involve changes in the dynamics of the epithelial stem cell population. 6 Crypt stem cells may play a central role in intestinal mucosal regeneration following injury. However, relatively little is known about the response of stem cells in intestinal epithelium to intestinal injury.
Although stem cell proliferation is an important step in epithelial injury repair, it has been difficult to study. Direct evaluation of stem cell function in this process is not feasible because there are few markers specific for gastrointestinal stem cells. Musashi-1 (Msi-1) is an RNA-binding protein, and it appears to be expressed in a few cells in the stem cell region of steady-state crypts. Msi-1 has been shown to be expressed in ISCs, and it has been considered a candidate marker for ISCs. 7, 8 Lgr5 was originally proposed as a marker of stem cells that reside at the crypts. The Lgr5 gene encodes an orphan G proteincoupled receptor, characterized by a large leucine-rich extracellular domain and highly expressed in stem cells. In situ hybridization on small intestinal tissue revealed the expression of the Lgr5 gene at the crypts. Recently, the Lgr5 gene has been shown to express in the stem cells of the small intestine and colon. 9 Alemtuzemab (Campath-1H; ILEX, San Antonio, TX, USA), a humanized anti-CD52 antibody, has been used therapeutically with increasing frequency for immunosuppressive induction in solid organ transplantation. [10] [11] [12] Moreover, alemtuzumab has been used for lymphodepletion in hematopoietic stem cell transplantation and for the treatment of chronic lymphocytic leukemia and multiple sclerosis. The use of alemtuzumab has changed the spectrum of infections in transplant patients, and it does not render patients more susceptible to viral or bacterial infections compared to conventional triple immunosuppression. 13 Infections still remain a significant cause of morbidity. 14, 15 Recently, our results revealed the alteration of tight junctions and the disruption of intestinal barrier function in intestinal transplantation with the use of alemtuzumab. 16 In this study, we examined the expression of Msi-1 and Lgr5 in small intestine after alemtuzumab administration. Our findings may have important implications for the critical role of ISCs when intestinal mucosa suffers injury and repair after alemtuzumab administration. available dry food and water ad libitum. Animals were maintained on a 12-h light/dark schedule in a barrier facility; the room temperature was set at 20-25 uC, and the humidity was adjusted to 50%-75%. Experiments were performed in accordance with the international guiding principles for biomedical research involving animals, and all procedures were approved by the ethics committee at our medical college.
Alemtuzumab was administered intravenously at a dose of 3 mg/kg. The animals were killed at 3, 9 and 35 days after alemtuzumab treatment by intramuscular injection of ketamine hydrochloride (four animals were used in each group). The intestine was removed and immediately snap-frozen for analysis.
Histopathological analysis
The ileal tissues were fixed in 10 % buffered neutral formalin. Fixed tissues were embedded in paraffin and cut into 5 mm thick sections. Sections were stained with hematoxylin and eosin.
Transmission electron microscopy
The ileal tissues were fixed in 4% glutaraldehyde in 0.1 M phosphatebuffered saline (PBS, pH 7.4) and kept at 4 uC. After several thorough washes in 0.1 M PBS, tissues were postfixed in 1% osmium tetroxide for 2 h. Specimens were then stained en bloc with uranylacetate and embedded in Epon resin. Subsequently, the tissues were sectioned, and the ultrathin sections were stained with uranylacetate and lead citrate. The sections were then viewed with a JEOL 1200EX transmission electron microscope (Hitachi, Tokyo, Japan) at 100 kV.
Tissue preparation and immunofluorescence
Ileal samples were opened with fine scissors and rinsed thoroughly with PBS. Tissue samples were embedded in OCT compound (Tissue-Tek O.C.T compound; Sakura Finetek USA, Inc., Torrance, CA, USA), sectioned on a cryostat (Leica, Wetzlar, Germany) and mounted on glass slides. Cryosections were acetone fixed for 15 min. They were then washed briefly in PBS and incubated for 20 min at room temperature with 5% goat serum in PBS. The sections were incubated with primary antibodies overnight at 4 uC. Sections were washed and incubated with secondary antibodies for 30 min and then washed three times in PBS for 2 min. Tissues were mounted using an aqueous medium containing 49,6-diamidino-2-phenylindole (DAPI) as a nuclear stain (Molecular Probes, Eugene, OR, USA). The distribution of the fluorescence signal was evaluated under a Leica TCS SP2 confocal scanning microscope (Leica Microsystems; Heidelberg GmbH, Mannheim, Germany).
The primary antibodies used included goat anti-Lgr 5 (1 : 250) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and rabbit Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) The TUNEL assay was performed using an Apoptag Fluorescein in situ Apoptosis Detection Kit (Chemicon International Inc., Temecula, CA, USA). In brief, frozen tissue sections (8 mm) were fixed in 1% paraformaldehyde for 10 min at room temperature. The samples were washed with PBS two times for 5 min and then incubated with ethanol/acetone (2 : 1) for 5 min at 220 uC. After being rinsed with PBS, sections were incubated with terminal deoxynucleotidyl transferase enzyme mixture for 60 min at 37 uC. The anti-digoxigenin antibody conjugated to fluorescein was applied to the tissues and incubated for 30 min. The slides were then wet-mounted and counterstained with DAPI. Tissues were viewed by laser confocal microscopy. DNA fragmentation was detected by localized green fluorescence of apoptotic cells (visualized by DAPI).
Scoring of apoptotic cells, Musashi
1 cells and Lgr 1 cells The number of apoptotic cells and ISCs per cross-section was determined for each animal by scoring the number of stained cells. Sections from four animals were used; 10 well-oriented villi or crypts were counted in each. The average numbers of apoptotic cells, Musashiand Lgr-positive cells were obtained.
Statistical analysis
All data were analyzed by ANOVA with SigmaStat 3.0 software and presented as means6s.e.m. P values of ,0.05 were considered statistically significant.
RESULTS

Effects of alemtuzumab on intestinal epithelium and crypts
To investigate the impact of alemtuzumab on intestinal homeostasis, we examined the pathological changes of the hematoxylin and eosinstained sections, and the nuclear DNA was stained with DAPI. The villi of animals treated with alemtuzumab for 3 and 9 days were lined by shorter, less dense enterocytes compared with those of the control (Figure 1 and Supplementary Figure 1) , which suggested a loss of intestinal epithelial cells after alemtuzumab treatment. We observed (Figures 1 and 2) . The results indicated that normal epithelial architecture was restored after intestinal injury caused by alemtuzumab treatment.
Examination of the crypts revealed profound abnormality of the Paneth cells in alemtuzumab-treated animals. Paneth cells were evident at the bases of crypts in normal intestine, and a large number of secretory granules were seen in the Paneth cells (Figures 1 and 3 and Supplementary Figure 2) . Paneth cell granules were reduced in number after alemtuzumab treatment for 3 and 9 days (Figure 3 and Supplementary Figure 2) . Abnormal Paneth cell morphology, including aberrant, disorganized granules, was found in Paneth cells. The Paneth cells exhibited normal morphology on day 35 after alemtuzumab treatment.
Ultrastructural alterations in the crypts
To more fully characterize the effects of alemtuzumab on crypts, we performed transmission electron microscopy. Transmission electron microscopy analysis of the ileum revealed ultrastructural changes to the crypts after alemtuzumab treatment. As shown in Figure 4 , in normal intestine, Paneth cells were characterized by a large number of electron-dense secretory granules in the cytoplasm. Typical crypt base columnar (CBC) cells were found to be interspersed between the Paneth cells. The CBC cells were small and slender, with high nuclear/ cytoplasmic ratios and scarce organelles. The number of secretory granules decreased dramatically in Paneth cells 3 days after alemtuzumab treatment compared with controls, with granules remaining in the apical part of the Paneth cells (Figure 4 ). On day 9 of alemtuzumab treatment, depletion of secretory granules from Paneth cells was more severe. Paneth cells from the animals treated with alemtuzumab for 35 days were similar to those of the controls (Figure 4) . Alemtuzumab treatment also resulted in degenerating mitochondria (Supplementary Figure 3) . A similar abnormality has also been reported in Paneth cells from ATG16L1-deficient mice. 17 . Notably, these findings were not present in the epithelial stem cell zone, suggesting that alemtuzumab selectively affected Paneth cells in crypts. Thus, we concluded from the extensive morphological abnormalities documented above that alemtuzumab treatment was associated with profound alterations in the specialized properties of Paneth cells.
Apoptosis in the villi and crypts
The effect of alemtuzumab on intestinal epithelial apoptosis was investigated by TUNEL staining. As shown in Figure 5 , apoptosis was rare in both the villi (three apoptotic cells per villus) and the crypts (0.3 apoptotic cells per crypt) in the control intestine tissues. At 3 days after alemtuzumab administration, the number of apoptotic cells increased by 2.1-fold in the villi (6.3 apoptotic cells per villus) and by 7.7-fold in crypts (2.3 apoptotic cells per crypt), respectively. In contrast, the density of apoptotic cells in the villi was indistinguishable from that of the control tissues on day 9 after alemtuzumab administration (3.7 apoptotic cells per villus). However, apoptotic cell density increased significantly in the ISC zone of the crypts on day 9 (four apoptotic cells per crypt). On day 35, alemtuzumab-treated animals displayed the same degree of apoptosis in the intestine as did control tissues.
Expression of Msi-1
To determine the response of ISC to the disruption of intestinal epithelium by alemtuzumab, we performed immunostaining for Msi-1, a putative marker of stem cells in the intestinal epithelium ( Figure 6 ). 
Lgr5 expression in crypts
To confirm the above observations, we used another ISC marker, Lgr5, to investigate the localization and expression pattern of stem cells in the crypts. Immunostaining revealed expression of Lgr5 (Figure 7 ) in the epithelial cells at the crypt base of normal small intestinal mucosa, similar to the pattern of Msi-1 expression. After alemtuzumab treatment, there was a notable increase in Lgr5-staining cells on days 3 and 9 (7.3 and 9 cells, respectively), which further confirmed the induction effects of alemtuzumab. The Lgr5 gene was thought to mark the cycling CBC cells interspersed between Paneth cells. In the present study, Lgr5-positive cells were found not to be restricted to the crypt base and were present in the upper parts of the crypts. Lgr5 staining had nearly returned to baseline level following 35 days of treatment with alemtuzumab, with an expression pattern similar to that observed in the control.
DISCUSSION
Our previous study demonstrated barrier impairment following intestinal transplantation in combination with alemtuzumab treatment. 16 An increase in intestinal permeability and a disruption of intestinal barrier function was also observed in CD52 treated mice due to the deletion of intestinal intraepithelial lymphocytes. 18 Several reports have demonstrated increased incidence of infection and intestinal villi atrophy during treatment with alemtuzumab.
14 The gut epithelium is constantly renewed by the division and differentiation of ISCs. The function of the stem cell is to maintain the integrity of the intestinal epithelium. The crypts of the small intestine have long been known to harbor a functional stem cell compartment. However, relatively little is known about the response of ISCs in the crypts after intestinal injury. The damage to stem cell proliferation in crypts resulting from exposure to alemtuzumab is poorly understood. Related sequelae including cellular and morphological changes in the ISCs remain to be elucidated. Because human CD52 monoclonal antibody does not always cross-react with other mammals' tissues and human epitopes are well conserved in apes and in monkeys, 19 we used macaques as an animal model for alemtuzumab treatment. In this report, we demonstrated that the villi of the macaques treated with alemtuzumab for 3 and 9 Alemtuzumab's effects on intestinal stem cells Q Li et al 330 days were lined by shorter, less-dense enterocytes; obvious abnormalities in Paneth cells were found (Figures 1 and 2) . A marked change was observed in intestinal crypt stem cells in animals treated with alemtuzumab for 3 and 9 days. Increased numbers of cells staining positive for both Msi-1 and Lgr 5 were found in the stem cell zone after alemtuzumab treatment (Figures 6 and 7) . These findings demonstrated the expansion of stem cell populations, triggered by the alemtuzumabmediated disruption of intestinal epithelial cells and Paneth cells.
We found that ISCs were regenerated in response to the damage that resulted from 3 or 9 days of alemtuzumab treatment. Apoptosis was induced in the intestinal epithelium, and a loss of intestinal epithelial cells as well as abnormal Paneth cell morphology was found following a single dose of alemtuzumab. These data suggest that gut homeostasis is maintained by the balance between epithelial damage resulting from alemtuzumab treatment and epithelial repair, mediated by the response of ISCs. Apoptosis provides an important protective mechanism for disposing of damaged cells. Epithelial cells at the small intestinal crypts are the first to undergo apoptosis following low-dose ionizing radiation. 20 Interestingly, we observed that induction of apoptosis by alemtuzumab localized to epithelial cells for the first 3 days of exposure and then traveled to the ISC zone after 9 days of exposure.
In addition to apoptosis occurring, the expansion of musash-1 and Lgr5-positive cells was induced after 3 and 9 days of alemtuzumab treatment. Alemtuzumab treatment induced apoptosis of epithelial cells, leading to the expansion of ISCs to repair epithelial injury. After alemtuzumab treatment for 35 days, the cell density of the intestinal epithelium and the number of ISCs returned to baseline levels, and there was no sign of apoptosis ( Figure 5) .
Identification of stem cells using reliable markers is essential to increase our understanding of the response of stem cells to intestinal injury. The current understanding is that two types of ISCs populate intestinal crypts 9, 21 (CBC cells and 14 ISC). Expression of the promising candidate marker Msi-1 appears to be restricted to stem cells and early progenitor cells. 21 Increased expression of Msi-1 in regenerative crypts is suggestive of a functional role for Msi-1 in crypt epithelial progenitor cell proliferation. Lgr5-positive cells, representing CBC cells), are currently believed to represent stem cells.
9 Lgr5-expressing cells can function as progenitors of all four epithelial lineages and Lgr5 may thus represent a more general marker of adult stem cells. 9 The existence of a pool of cycling stem cells defined by Lgr5 expression was recently demonstrated. 9, 22 Here, we also attempted to identify which cells in the ISC zone were regenerated in response to alemtuzumab treatment (i.e., putative 14 ISCs versus CBC cells). Staining for Msi-1-and Lgr5-positive cells showed that numbers of both Msi-1-and Lgr5-expressing cells were increased after alemtuzumab treatment for 3 and 9 days (Figures 6 and 7) . The numbers of Msi-1-and Lgr5-positive cells in intestinal crypts returned to control levels by 35 days after the initiation of alemtuzumab treatment. A single dose of alemtuzumab resulted in a rapid, transient depletion of T and B lymphocytes. In a Alemtuzumab's effects on intestinal stem cells Q Li et al 331 recent study of organ transplant patients receiving alemtuzumab immunodepletion therapy, patients experienced profound long-term T-cell depletion. 23 In our study, the absolute cell counts for lymphocytes in the peripheral blood of alemtuzumab-treated macaques were determined. The lymphocyte counts were markedly reduced, but then returned to the pretreatment level at 35 days (data not shown). Intestinal epithelium had also recovered functionality at day 35.
Based on these results, we propose that alemtuzumab treatment induced apoptosis of intestinal epithelial cells, leaving ISCs relatively untouched and allowing for the rapid expansion and regeneration of affected villi. Intestinal stem/progenitor cells were important for the epithelial repair of intestinal injury due to alemtuzumab treatment. The mechanism by which ISCs expand following alemtuzumab treatment is unclear. ISC expansion also occurred during intestinal development 24, 25 and following ileocecal resection in mice. 26 It is likely that the ISCs undergo symmetric cell division, effectively increasing the ISC number, and then driving the expansion of intestinal crypts by crypt fission when intestinal mucosa suffers injury. Additional research is needed to elucidate the mechanisms that activate ISC expansion during intestinal injury.
